Overview

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Status:
Terminated
Trial end date:
2015-12-25
Target enrollment:
Participant gender:
Summary
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Gedatolisib